GERMANTOWN, Md., June 13, 2019 /PRNewswire/ -- Intrexon
Corporation (NASDAQ: XON), a leader in the engineering
and industrialization of biology to improve the quality of life and
health of the planet, and its wholly-owned Intrexon Health
subsidiary Precigen, Inc., a biopharmaceutical company specializing
in the development of innovative gene and cellular therapies to
improve the lives of patients, today announced their presentation
at the JMP Securities Life Sciences Conference in New York. Helen
Sabzevari, PhD, President of Precigen, will highlight
Intrexon Health and Precigen in the presentation on Thursday, June 20, 2019 at 12:30 pm Eastern Time.
A live webcast of the presentation will be available on the
Investors section of Intrexon's website under 'Events'
at investors.dna.com/events and on Precigen's website
under 'Presentations' at www.precigen.com/media/#id-presentations.
The presentation will be archived on the Intrexon and Precigen
websites for 30 days following the event.
About Intrexon Corporation
Intrexon Corporation
(NASDAQ: XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products that improve
the quality of life and the health of the planet through two
operating units – Intrexon Health and Intrexon
Bioengineering. Intrexon Health is focused on addressing
unmet medical needs through a diverse spectrum of therapeutic
modalities, including gene and cell therapies, microbial
bioproduction, and regenerative medicine. Intrexon
Bioengineering seeks to address global challenges across food,
agriculture, environmental, and industrial fields by advancing
biologically engineered solutions to improve sustainability and
efficiency. Our integrated technology suite provides
industrial-scale design and development of complex biological
systems delivering unprecedented control, quality, function, and
performance of living cells. We call our synthetic biology approach
Better DNA®, and we invite you to discover more at
www.dna.com or follow us on Twitter at @Intrexon, on Facebook,
and LinkedIn.
Precigen: Advancing Medicine with
Precision™
Precigen is a dedicated discovery and
clinical stage biopharmaceutical company advancing the next
generation of gene and cellular therapies using precision
technology to target the most urgent and intractable diseases in
immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen also follows the science opportunistically in pursuit of
promising programs in emerging therapeutics. Our technologies
enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated unique therapies toward clinical
proof-of-concept and commercialization. Precigen was founded as a
wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and
leverages Intrexon's proprietary technology platforms to advance
human health. For more information about Precigen, visit
www.precigen.com or follow us on Twitter @Precigen and
LinkedIn.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to plans,
objectives and expectations for the development of our business,
including the timing and progress of preclinical and clinical
trials and discovery programs. Although management believes that
the plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release.
Intrexon Investor
Contact:
|
Intrexon Corporate
Contact:
|
Precigen Media
Contact:
|
Steven
Harasym
|
Marie Rossi,
PhD
|
Donelle M.
Gregory
|
Vice President,
Investor Relations
|
Vice President,
Communications
|
press@precigen.com
|
Tel: +1 (301)
556-9850
|
Tel: +1 (301)
556-9850
|
|
investors@dna.com
|
publicrelations@dna.com
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/intrexons-subsidiary-precigen-to-present-at-the-jmp-securities-life-sciences-conference-300866922.html
SOURCE Intrexon Corporation; Precigen, Inc.